<DOC>
	<DOCNO>NCT00095108</DOCNO>
	<brief_summary>This study do see experimental drug call recombinant interleukin-21 ( rIL-21 ) give patient stage 4 malignant melanoma stage 4 kidney cancer safe effect type cancer .</brief_summary>
	<brief_title>Study Interleukin-21 Metastatic Malignant Melanoma Metastatic Kidney Cancer</brief_title>
	<detailed_description>This phase 1 safety study . Everyone enrol eligible give rIL-21 . The study 2 part , Part A determine high dose rIl-21 safely give patient type cancer . Part B determine drug benefit patient type cancer . Part A may 7 different dose group . Beginning low dose , 3 patient treat watched side effect . If side effect severe , next group 3 patient recieve high dose . This cycle repeat high tolerated dose group find .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>18 year old stage 4 metastatic malignant melanoma stage 4 metastatic kidney cancer ECOG status 0 1 Patients must adequate liver , kidney bone marrow function Known ocular melanoma Suspected confirm brain metastasis Patient bone marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
</DOC>